<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715988</url>
  </required_header>
  <id_info>
    <org_study_id>24569</org_study_id>
    <secondary_id>1U10HD045986-01</secondary_id>
    <nct_id>NCT00715988</nct_id>
  </id_info>
  <brief_title>Methadone Pharmacokinetics and Cardiac Effects in Newborns</brief_title>
  <official_title>Safety and Single Dose Population Pharmacokinetics and Bioavailability of Methadone and Its Enantiomers in Newborns and Young Infants At 29-48 Weeks Post Menstrual Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary objectives of this proposal are to determine the population kinetics for
      methadone and its enantiomers in preterm newborns and infants at 29 weeks to 48 weeks post
      menstrual age (PMA) who are 1 week old and older and establish any correlations of the
      kinetics with PMA to determine the bioavailability for enterally administered methadone in
      these newborns and young infants.

      The secondary objectives of this proposal are to explore possible genotypic changes in
      CYP3A4-3A7-3A5, CYP2B6, CYP2C8, CYP2C19, and CYP2D6 and PGO on the kinetics of methadone in
      neonates and young infants and to test the safety of methadone in this population by
      correlating the plasma concentrations of the methadone enantiomers, S-methadone and
      R-methadone, with changes in cardiac repolarization by measurement of corrected QT, heart
      rate, and blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Painful procedures are frequent during the NICU care of sick newborns. Newborns are capable
      of perceiving pain by the time in fetal development when they reach our current limits of
      viability around 23-24 weeks post menstrual age.1 Painful procedures include suctioning
      during mechanical ventilation, thoracostomy tube placement, heel lance and venipuncture for
      blood sampling, and care following surgical procedures such as PDA ligation and bowel
      resection. Simons et al recently reported on the number of painful procedures in a large NICU
      in Rotterdam and provided a review of the frequency of such procedures from other NICU's.2
      This review shows that before discharge from the NICU, newborns may experience as many as 376
      painful procedures and as many as 61 painful procedures in a single day (or more if all
      procedures were not observed or reported). The most frequent procedures were heel lance and
      suctioning, both associated with the need for mechanical ventilation. Topical treatment of
      pain from heel lance has not been successful with EMLA3 or tetracaine.4

      During initial NICU care for infants supported with mechanical ventilation, systemic
      analgesia is usually provided with parenteral treatment with fentanyl or morphine. Most
      neonates are extubated soon after birth, and continued systemic treatment with analgesics is
      not needed. Other neonates have problems associated with chronic pain or continued painful
      procedures, such as surgical problems, chronic lung disease, airway anomalies, pulmonary
      hypoplasia and pulmonary hypertension following ECMO and congenital diaphragmatic hernia
      repair. These patients often require mechanical ventilation for weeks and sometimes months.
      During that prolonged care, systemic analgesia is changed to enteral dosing to reduce risks
      of infection associated with central catheters and to reduce the number of intravenous
      catheter insertions.

      Morphine and fentanyl administered enterally do not provide reliable systemic concentrations
      and effects due to first-pass metabolism. Fentanyl undergoes first-pass metabolism by CYP3A4
      during passage through the intestines and liver. Morphine undergoes first pass hepatic
      metabolism primarily by UGT2B7. In addition for morphine, one of its major metabolites, the
      3-glucuronide, is anti-analgesic and can cause dysphoria. An effective and well-characterized
      systemic analgesic that can be administered enterally is needed for the care of infants who
      require prolonged analgesic treatment and methadone can meet those needs.

      Methadone treatment in adults provides effective systemic analgesia after enteral
      administration through binding to the mu opioid receptor with a wide range of reported
      half-lives of 5 to 130 hrs,5 2 to 50 hrs,6 and 33 to 46 hrs; 7 and bioavailability ranging
      from 41 to 95%.8, 9

      Recently, methadone was reported to prolong QTc in adults receiving large doses of methadone
      during chronic treatment, often with additional predisposing factors for QT prolongation.
      Methadone is dispensed in a racemic mixture whose enantiomers have different potency for
      analgesia and for binding to the myocardium to potentially prolong QT. In addition the
      different enantiomers exhibit complex kinetics in adults as they undergo metabolism,
      primarily by CYP3A4, CYP2B6, and CYP2C19. This study will evaluate kinetics and
      bioavailability of methadone enantiomers and its effects on QT of neonates and young infants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 10, 2017</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Find the population kinetics for methadone and its enantiomers in preterm newborns and infants at 29 weeks to 48 wks PMA who are 1 week old and older</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the effects of R and S enantiomers of methadone on QT interval in newborns</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Scheme 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are feeding or not feeding and mechanically ventilated, &gt;/=3 d of age and 29 0/7wks-48 6/7 wks PMA, treated with i.v. bolus doses or infusion of fentanyl, morphine or methadone for clinical indications, with arterial/venous line in place &amp; expected treatment for at least 1-2 more days. Pk sampling = 0.5 ml blood samples x6/infant. ECG monitoring. Three patients will be enrolled in 5 PMA groups. Should apnea or hypotension occur, dosages for Treatment Scheme 2 will be reduced (50%); more patients will be studied in Treatment Scheme 1 to insure that the lower dose is well tolerated &amp; effective.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scheme 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients defined in Scheme 1, tolerating feeds for &gt;/= 3 days will be studied twice, after i.v. methadone and after enteral methadone after the end of sampling after the first dose. 4-5 samples will be obtained after dose 1 and after dose 2 depending on PMA and weight. Patients will be divided into groups based on PMA..</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone HCl Inject 10 mg/ml (will require dilution)</intervention_name>
    <description>Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)</description>
    <arm_group_label>Scheme 2</arm_group_label>
    <other_name>Dolophine, Methadose, Methadose Oral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose</description>
    <arm_group_label>Scheme 1</arm_group_label>
    <other_name>Dolophine, Methadose, Methadose Oral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Patients must be in the NICU or PICU with continuous cardiorespiratory monitoring

          2. PMA between 29 0/7 to 48 6/7 weeks (EGA at birth (wks) + postnatal age wks) at the
             start of study

          3. Weight &gt;1499 gm at the time of enrollment

          4. Postnatal age of 3 days or more

          5. Arterial or venous catheter suitable for blood sampling with a separate i.v. infusion
             site is preferred, but not essential

          6. Currently being treated with methadone bolus doses or fentanyl or morphine in bolus
             doses or by infusion for clinical indications and expected to be treated for at least
             1-2 more days with opioids for study of single dose pharmacokinetics and to be treated
             for 3-5 days more during the study of bioavailability

          7. Hematocrit â‰¥35%

          8. Parental permission

          9. Approval by the patient's attending physician

             Treatment Scheme 1, studied for 48 hr after a single i.v. dose of methadone

         10. Feeding or not feeding

         11. Mechanically ventilated

             Treatment Scheme 2 studied for 24 to 48 hr after a single i.v. dose of methadone AND
             again after a single enteral dose of methadone after the end of sampling after the
             first dose; order of doses is randomized. If the caregiver feels the patient is too
             sedated at the end of pK sampling after Dose, 1, then Dose 2 will be delayed until
             patient is judged to need analgesic treatment.

         12. Tolerating enteral feeding for 3 consecutive days before study

        EXCLUSION CRITERIA

          1. Clinically diagnosed liver dysfunction

          2. Clinically diagnosed kidney dysfunction with urine output &lt;1.0 ml/kg/hr

          3. Gastrointestinal malformation or dysfunction that might interfere with enteral drug
             absorption

          4. Congenital anomalies or other conditions thought to be incompatible with life

          5. History of arrhythmias, excluding bradycardia associated with apnea

          6. Unstable cardiorespiratory status

          7. Serum K+ &lt;3.0 mEq/L

          8. QTc[H] &gt;0.449 ms using Hodges correction =QT + 1.75(rate - 60).

          9. Family history of unexplained early cardiac deaths, syncope, or long QT syndrome in
             primary relatives: siblings, parents, grandparents, or aunts/uncles.

         10. Treatment with inhibitors and inducers of CYP3A4, CYP2B6, CYP2D6 and PGP including:

        amiodarone, carbamazepine, ciprofloxacin, clarithromycin, clotrimazole, dexamethasone,
        erythromycin, ethosuximide, fluconazole, fluoxetine, fluvoxamine, grapefruit juice,
        indinavir, itraconazole, ketoconazole, metronidazole, miconazole, nelfinavir, paroxetine,
        phenobarbital, phenytoin, quercetin, quinidine, rifabutin, rifampin, ritonavir, saquinavir,
        sulfadimidine, sulfinpyrazone, troleandomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>29 Weeks</minimum_age>
    <maximum_age>48 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ward, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>April 8, 2017</last_update_submitted>
  <last_update_submitted_qc>April 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Robert Ward</investigator_full_name>
    <investigator_title>Professor, Pediatrics; Adjunct Professor, Pharmacology/Toxicology</investigator_title>
  </responsible_party>
  <keyword>Methadone</keyword>
  <keyword>analgesia</keyword>
  <keyword>newborns</keyword>
  <keyword>QT prolongation</keyword>
  <keyword>Young Infants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data shared with other investigators leading to publication of the pediatric population pharmacokinetics of methadone</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

